Loading clinical trials...
Loading clinical trials...
The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.
Conditions
Interventions
LGX818
MEK162
+4 more
Locations
32
United States
University of California Los Angeles
Los Angeles, California, United States
Cancer Care Center
Los Angeles, California, United States
Doris Stein Research Center Building
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services
Los Angeles, California, United States
UCLA Dermatology Clinic
Los Angeles, California, United States
UCLA Oncology Center
Los Angeles, California, United States
Start Date
July 23, 2014
Primary Completion Date
January 10, 2023
Completion Date
January 10, 2023
Last Updated
March 5, 2024
NCT05969860
NCT03340506
NCT04693377
NCT05111574
NCT04895709
NCT06500455
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions